Loading…
Bicycle Therapeutics plc is projected to rise to $4.49 by 2027, a +2% move from its current price of $4.41. BCYC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.32 | $4.41 | $4.50 | -0.01% |
| Jul 14 | $4.28 | $4.41 | $4.54 | -0.02% |
| Jul 15 | $4.26 | $4.41 | $4.57 | -0.03% |
| Jul 16 | $4.23 | $4.41 | $4.59 | -0.04% |
| Jul 17 | $4.21 | $4.41 | $4.61 | -0.06% |
| Jul 18 | $4.19 | $4.41 | $4.63 | -0.07% |
| Jul 19 | $4.18 | $4.41 | $4.65 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.18 | $4.41 | $4.65 | -0.08% |
| Week 2 | $4.08 | $4.40 | $4.75 | -0.16% |
| Week 3 | $4.01 | $4.40 | $4.83 | -0.23% |
| Week 4 | $3.95 | $4.40 | $4.89 | -0.31% |
| Week 5 | $3.90 | $4.39 | $4.95 | -0.39% |
| Week 6 | $3.85 | $4.39 | $5.01 | -0.47% |
| Week 7 | $3.81 | $4.39 | $5.05 | -0.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bicycle Therapeutics plc is a clinical-stage pharmaceutical company that develops a class of medicines for diseases underserved by existing therapeutics in the United States and the United Kingdom.
Its product pipeline includes zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical.
The company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
BCYC is currently trading at $4.35 with a market cap of $303.68M and ranks 3523. The current price reflects the stock’s standing in the market, while the forecast paints a probabilistic path through 2026–2050 with growing upside starting in the 2030s.
The 2026–2029 forecast shows modest near-term activity, with 2026 min $3.96, avg $4.35, max $5.39; 2027 min $3.64, avg $4.44, max $5.67; 2028 min $3.64, avg $4.53, max $5.95; 2029 min $3.75, avg $4.74, max $6.34. From 2030 onward, the forecast turns more bullish, with 2030 avg $5.54 and max $7.55 (ROI 27.4%), 2040 avg $8.93 and max $13.62 (ROI 105.3%), and 2050 avg $18.47 and max $30.20 (ROI 324.5%).
Overall, the outlook indicates a path of increasing value in the long term, with the strongest gains projected beyond the next decade.
A major floor 17.8% below — a decisive break under it would weaken the trend.
The nearest floor, 10.2% below — buyers have tended to step in here.
The nearest ceiling, 6.3% above — a clean break opens room to run.
A major ceiling 27.7% above — clearing it would confirm fresh momentum.
Key BCYC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCYC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.32 | Buy | $4.31 | Buy |
| MA 10 | $4.26 | Buy | $4.26 | Buy |
| MA 20 | $4.15 | Buy | $4.24 | Buy |
| MA 50 | $4.39 | Buy | $4.40 | Buy |
| MA 100 | $4.72 | Sell | $4.84 | Sell |
| MA 200 | $5.90 | Sell | $5.94 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.05 | Neutral |
| Stoch RSI (14) | 98.02 | Sell |
| CCI (20) | 143.17 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 10.25 | Buy |
| Bollinger %B (20,2) | 0.96 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.20 | Sell |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 62.76 | Neutral |
| Momentum (10) | 0.40 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 4.31 | Buy |
| ADX (14) | 16.47 | Neutral |
| ATR (14) | 0.08 | Info |
The short-term technical picture is neutral. The current sentiment is NEUTRAL with RSI(14) at 60, suggesting a balance between buyers and sellers.
Near-term moving averages show SMA50 at $4.44 and SMA200 at $5.97, indicating that the longer-term average remains higher than the near-term price.
Key levels to watch are support at $3.96 and resistance at $4.69, with the 30-day range spanning $3.86 to $4.91. The stock has an annualized volatility of 30%, highlighting notable short-term price fluctuations within this window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.96 | $4.41 | $5.42 | 0% | Neutral | |
| $3.66 | $4.49 | $5.77 | +2% | Neutral | |
| $3.67 | $4.59 | $6.07 | +4% | Neutral | |
| $3.69 | $4.70 | $6.36 | +7% | Neutral | |
| $4.28 | $5.53 | $7.62 | +25% | Bullish | |
| $4.73 | $6.19 | $8.68 | +40% | Bullish | |
| $4.63 | $6.13 | $8.72 | +39% | Bullish | |
| $4.73 | $6.34 | $9.14 | +44% | Bullish | |
| $4.69 | $6.36 | $9.28 | +44% | Bullish | |
| $4.81 | $6.58 | $9.73 | +49% | Bullish | |
| $6.20 | $8.88 | $13.78 | +101% | Bullish | |
| $11.66 | $18.03 | $30.13 | +309% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.96 | $4.41 | $5.14 | +0.00% |
| August 2026 | $3.65 | $4.28 | $5.13 | -2.87% |
| September 2026 | $3.71 | $4.37 | $5.28 | +1.92% |
| October 2026 | $3.71 | $4.39 | $5.35 | +0.66% |
| November 2026 | $3.65 | $4.33 | $5.31 | -1.38% |
| December 2026 | $3.70 | $4.41 | $5.42 | +1.69% |
Click any year to see its month-by-month BCYC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BCYC price prediction for 2026 points to an average of $4.41 (low $3.96, high $5.42) — a potential gain of 0% on today's $4.41. Price action looks broadly range-bound.
In 2027, BCYC is projected to trade between $3.66 and $5.77, averaging $4.49 — a potential gain of +2% from today's $4.41. That is up +2% on the projected 2026 average. A consolidation phase looks the most probable path here.
Bicycle Therapeutics plc's 2028 outlook centres on $4.59, within a $3.67 to $6.07 range. That is up +2% on the projected 2027 average. That marks a +4% change versus current levels. Price action looks broadly range-bound.
By 2029, BCYC could reach as high as $6.36, with a base case around $4.70 and support toward $3.69 — roughly +7% from $4.41. A consolidation phase looks the most probable path here.
Expect BCYC to range from $4.28 to $7.62 through 2030. The $5.53 average target implies a +25% move from current prices. That is up +18% on the projected 2029 average. Momentum favours further upside here.
The BCYC price prediction for 2031 points to an average of $6.19 (low $4.73, high $8.68) — a potential gain of +40% on today's $4.41. Buyers look set to stay in control over this stretch.
In 2032, BCYC is projected to trade between $4.63 and $8.72, averaging $6.13 — a potential gain of +39% from today's $4.41. That is -1% versus the projected 2031 average. Momentum favours further upside here.
Bicycle Therapeutics plc's 2033 outlook centres on $6.34, within a $4.73 to $9.14 range. That is up +3% on the projected 2032 average. That marks a +44% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, BCYC could reach as high as $9.28, with a base case around $6.36 and support toward $4.69 — roughly +44% from $4.41. Momentum favours further upside here.
Expect BCYC to range from $4.81 to $9.73 through 2035. The $6.58 average target implies a +49% move from current prices. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The BCYC price prediction for 2040 points to an average of $8.88 (low $6.20, high $13.78) — a potential gain of +101% on today's $4.41. Momentum favours further upside here.
In 2050, BCYC is projected to trade between $11.66 and $30.13, averaging $18.03 — a potential gain of +309% from today's $4.41. That is up +103% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BCYC today (≈ 226.75737 BCYC) could be worth
$4,088.88
+$3,088.88 (+309%) by 2050 · US Dollar
Based on the average projected BCYC price of $18.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCYCwould be worth at today's price.
$1,000 invested in BCYC on Jul 10, 2025 (≈ 123.609392 BCYC) would be worth
$545.12
-$454.88 (-45.5%) today · 0.55× · US Dollar
Based on a BCYC entry price of $8.09 vs. today's $4.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.35 | $1,013.79 | +1.4% |
| 1 month ago | $4.03 | $1,094.29 | +9.4% |
| 3 months ago | $4.94 | $892.71 | -10.7% |
| 6 months ago | $6.58 | $670.21 | -33.0% |
| 1 year ago | $8.09 | $545.12 | -45.5% |
| All time (5.0y) ago | $32.87 | $134.16 | -86.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCYC forecast.
Our base-case forecast reaches $8.80 around 2040.
Implied market cap at $8.80: $443.28M
The multi-year forecast turns bullish from 2030 onward, with 2030 avg price of $5.54 and ROI of 27.4, signaling meaningful upside from current levels. The 2040 forecast shows an avg of $8.93 and ROI of 105.3, reinforcing the longer-term upside trajectory toward higher price levels.
By 2050 the forecast projects an avg of $18.47 with ROI of 324.5, and a max of $30.20, underscoring substantial potential upside if the trajectory plays out. These numbers imply rising valuations as the pipeline progresses and therapeutic programs advance, though the figures are estimates and not guarantees. Risks and uncertainties inherent to clinical development and market dynamics could affect actual outcomes.
In sum, the outlook suggests increasing value over the long term, with bullish sentiment intensifying after 2030 and the potential for substantial appreciation by 2050, contingent on various factors unfolding as forecasted.
Tap a question to reveal the answer.
min $4.33, avg $5.54, max $7.55; ROI 27.4; sentiment BULLISH.
The forecast shows bullish sentiment from 2030 onward, with avg price rising to $5.54 by 2030 and to $18.47 by 2050 and ROI up to 324.5% by 2050.
Yes. The 2040 max is $13.62 and the 2050 max is $30.20, indicating the possibility of reaching and exceeding $10 by 2040.
Current price $4.35; Market cap $303.68M.
min $4.77, avg $6.18, max $8.56; ROI 42.1; sentiment BULLISH.
Bicycle Therapeutics plc Community Discussion
0Share your Bicycle Therapeutics plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.